Press release
Carcinoid Tumor Market Size, Epidemiology, Leading Companies, Drugs, Pipeline Therapies and Competitive Analysis by DelveInsight
DelveInsight's "Carcinoid Tumor Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Carcinoid Tumor , historical and forecasted epidemiology as well as the Carcinoid Tumor market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.Some key facts of Carcinoid Tumor Market Report:
1. Literature studies suggest that women are more likely to develop carcinoid tumors than men.
2. The incidence of Neuroendocrine tumors was approximately 2/100,000 with a female preponderance under the age of 50 years due to appendiceal location. The main primary sites were the gastrointestinal tract (62-67%) and the lung (22-27%). Presentation with metastatic disease accounts for 12-22%.
3. According to the American Society of Clinical Oncology (ASCO) in 2016, approximately 8,000 adults in the US were diagnosed with a carcinoid tumor in their GI tract.
4. It is estimated that each year approximately 4,000 adults in the United States diagnose with the carcinoid tumor in their lung.
5. Expected launch of Nivolumab + Cabozantinib, Pembrolizumab and other emerging drugs for treating CT shall fuel the growth of the market
Find a sample copy of the Carcinoid Tumor Market report - https://www.delveinsight.com/report-store/carcinoid-tumor-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Carcinoid Tumor Report:
• The Carcinoid Tumor report covers the descriptive overview of Carcinoid Tumor , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Carcinoid Tumor epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Carcinoid Tumor are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Carcinoid Tumor market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The Carcinoid Tumor report provides an edge while developing business strategies, by understanding trends shaping and driving the global Carcinoid Tumor market
Request a sample and discover more about the scope of the report offerings: https://www.delveinsight.com/report-store/carcinoid-tumor-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Carcinoid Tumors are a type of slow-growing cancers that can arise in several places throughout the body and are characterized by the production of an excess of hormone-like substances, such as serotonin, bradykinin, histamine, and prostaglandins which leads to the other associated complications. These tumors, are the subset of neuroendocrine tumors and usually begin in the digestive tract (stomach, appendix, small intestine, colon) or in the lungs. On the basis of their location of origin, these tumors are categorized into three areas as Foregut: The foregut includes the lungs and the stomach; Midgut: comprised of the small intestine, appendix, and the beginning of the large bowel (colon), and Hindgut: composed of the end of the large bowel, and the organs of the genitourinary tract (ovaries, testes).
For further information on the Carcinoid Tumor current pipeline therapeutics, reach out: https://www.delveinsight.com/report-store/carcinoid-tumor-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
In the terms of their reported occurrence, CT most commonly develops in the gastrointestinal tract. However, they can also occur in other parts of the body such as the lungs, ovaries, or testicles. Based on the location and size of the tumor, CT usually presents with the subset of the symptoms such as cutaneous flushing, itching, and palpitation, edema, salivation, upper body erythema, chronic diarrhea, malabsorption, and breathing difficulties, etc. Till now, the associated causes of CT remains largely unknown, however common risk factors includes getting affected with disorders, such as multiple endocrine neoplasia, pernicious anemia, or Zollinger- Ellison syndrome, etc.
Find out more about the disease and recently developing strategies: https://www.delveinsight.com/report-store/carcinoid-tumor-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
The Key players involved in the Carcinoid Tumor market are:
1. Amgen Inc.
2. Novartis AG
3. Exelixis, Inc.
4. AVEO Pharmaceuticals, Inc.
5. Boehringer Ingelheim GmbH
6. Aegis Therapeutics, LLC
7. Chiasma, Inc.
8. Delcath Systems Inc.
9. CRINETICS PHARMACEUTICALS
And Many Others.
Dive deep into rich insights for emerging drugs and pipeline assessment, visit: https://www.delveinsight.com/sample-request/carcinoid-tumor-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents:
1. Key Insights
2. Executive Summary of Carcinoid Tumor
3. Competitive Intelligence Analysis for Carcinoid Tumor
4. Carcinoid Tumor : Market Overview at a Glance
5. Carcinoid Tumor : Disease Background and Overview
6. Patient Journey
7. Carcinoid Tumor Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Carcinoid Tumor Unmet Needs
10. Key Endpoints of Carcinoid Tumor Treatment
11. Marketed Products
List to be continued in report
12. Emerging Therapies
List to be continued in report
13. Carcinoid Tumor : Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Carcinoid Tumor
17. KOL Views
18. Carcinoid Tumor Market Drivers
19. Carcinoid Tumor Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Get the TOC of the Carcinoid Tumor Market report here:
https://www.delveinsight.com/sample-request/carcinoid-tumor-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Ankit Nigam
Email: info@delveinsight.com
Phone: +19193216187
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
DelveInsight is a leading Life Science market research and business consulting company recognised for its off-the-shelf syndicated market research reports as well as customised solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Carcinoid Tumor Market Size, Epidemiology, Leading Companies, Drugs, Pipeline Therapies and Competitive Analysis by DelveInsight here
News-ID: 2601675 • Views: …
More Releases from DelveInsight Business Research
Gastric Cancer Market to Exceed USD 700 Million in HER2+ Segment by 2034 Across …
Gastric cancer is the fifth most common malignancy worldwide, with incidence varying by region and highest rates reported in Eastern Asia and Eastern Europe. Japan records the highest burden among the 7MM, with about 129,500 cases in 2024. Many patients, particularly in Western countries, are diagnosed at advanced (Stage IV) stages, while Japan detects more cases early (Stage I). In the US, around 35% present with metastatic disease at diagnosis,…
Myelofibrosis Market to Double by 2034, Surpassing USD 5.6 Billion Across 7MM wi …
The Myelofibrosis market across the seven major markets (7MM) is anticipated to experience significant growth, rising from approximately USD 2,602 million in 2025 to nearly USD 5,638 million by 2034, reflecting a compound annual growth rate (CAGR) of about 9% during the forecast period.
In 2024, the market was valued at around USD 2.2 billion, with the United States leading at nearly USD 1.7 billion, far surpassing the EU4, the United…
Triple-Negative Breast Cancer Clinical Trial Landscape Expands With 170+ Pipelin …
An expanding portfolio of novel therapies for triple-negative breast cancer (TNBC) including TECENTRIQ (Hoffmann-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (CytoDyn), MDNA11 (Medicenna Therapeutics), VIP236 (Vincerx Pharma), and CFI-400945 (Treadwell Therapeutics) is anticipated to significantly influence market expansion and transform the TNBC treatment landscape.
DelveInsight's Triple Negative Breast Cancer Pipeline Insight report offers an extensive evaluation of more than 165 companies and over 170 therapeutic candidates advancing through the TNBC pipeline. The…
Asthma Market to Witness Steady Growth Through 2034 Driven by Novel Biologics an …
DelveInsight's latest Asthma Market Insights, Epidemiology, and Market Forecast - 2034 report provides an in-depth evaluation of current treatment practices, emerging asthma drugs, market share of individual therapies, and forecasted market trends across the seven major markets (7MM) - the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The asthma market is expected to experience sustained growth over the next decade, supported by the launch of…
More Releases for Carcinoid
Carcinoid Syndrome Management Market Is Going to Boom |• Novartis • Ipsen
Worldwide Market Reports has recently published an in-depth research study titled "Carcinoid Syndrome Management Market Size and Forecast 2026-2033: Analysis by Manufacturers, Key Regions, Product Types, and Applications." The report is developed using a robust blend of primary and secondary research methodologies, ensuring accuracy, reliability, and comprehensive market coverage. Leveraging historical data and forward-looking projections, the study presents a detailed evaluation of the Carcinoid Syndrome Management market growth, analyzing trends…
Carcinoid Syndrome Market is expected to reach USD 3.5 billion by 2034
Carcinoid syndrome is a rare but serious condition that develops when neuroendocrine tumors (NETs) produce excess hormones such as serotonin. Patients often experience flushing, diarrhea, abdominal cramping, and heart complications. While carcinoid syndrome is relatively uncommon compared to other oncological conditions, its impact on patient quality of life and long-term survival is profound.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71185
With neuroendocrine tumor incidence steadily increasing worldwide, the need…
Global Carcinoid Syndrome Management Market Will Generate Record Revenue by 2028
This Carcinoid Syndrome Management market report contains a wealth of information about future breakthroughs and innovations. It goes on to discuss the impact of these developments on the market's overall economic growth. This Carcinoid Syndrome Management market report is also beneficial to industries in understanding the essential issues and opportunities that manufacturers face in the workplace. The impact of the COVID-19 pandemic on the market is predicted to be detrimental.…
Carcinoid Syndrome Diarrhea Treatment Market - Increasing prevalence of rare car …
Carcinoid Syndrome Diarrhea Treatment Market report is a exploration database spread across colorful runners with multiple tables and numbers in it. The exploration covers a precious source of perceptive information for business strategists. Carcinoid Syndrome Diarrhea Treatment Industry provides the overview with growth analysis and literal & futuristic cost, profit, demand and force data (as applicable). The exploration judges give an elegant description of the value chain and its distributor…
Carcinoid Syndrome Diarrhea Treatment Market Size, Status and Forecast To
Carcinoid Syndrome Diarrhea Treatment Market
The Global Carcinoid Syndrome Diarrhea Treatment Market research report provides a unique methodology for evaluating the market insights, highlighting opportunities and supporting strategic and tactical decision-making. This report recognizes the requirement of a rapidly-evolving and competitive environment, up-to-date marketing information is essential to monitor performance and make critical decisions for growth and profitability. It provides information on the latest trends and developments and focuses on innovations…
Carcinoid Syndrome Management Market to Witness Exponential Growth by 2027
Carcinoid syndrome comprises of signs and symptoms such as flushing of the face, debilitating diarrhea, asthma caused due to vasoconstriction, intestinal bleeding, fast heartbeat, shortness of breath, sweating, unexplained weight gain etc. which are developed secondary to carcinoid tumor. The term ‘carcinoid crisis’ is used when all the symptoms of carcinoid syndrome show at a time. Carcinoid tumors arise out of neuroendocrine cells which are present all over the human…
